Carmen Aguilera

Leon, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.

Journal: British journal of haematology

Published: November 29, 2021

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.

Journal: British journal of haematology

Published: May 18, 2020

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

Journal: Haematologica

Published: October 14, 2016

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Journal: Leukemia

Published: February 22, 2016

Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders.

Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 22, 2015

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.

Journal: Leukemia

Published: December 29, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026